Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Top Cited Papers
- 1 August 2012
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 380 (9842) , 651-659
- https://doi.org/10.1016/s0140-6736(12)60988-x
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Lebrikizumab Treatment in Adults with AsthmaNew England Journal of Medicine, 2011
- Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trialThe Lancet, 2011
- Refractory asthma in the UK: cross-sectional findings from a UK multicentre registryThorax, 2010
- Mepolizumab in refractory eosinophilic asthmaThorax, 2010
- Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research ProgramAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisitedEuropean Respiratory Journal, 2008
- Near‐fatal asthma phenotype in the ENFUMOSA CohortClinical and Experimental Allergy, 2007
- Development and validation of a questionnaire to measure asthma controlEuropean Respiratory Journal, 1999
- The costs of asthmaEuropean Respiratory Journal, 1996
- Steroid-Induced Fractures and Bone Loss in Patients with AsthmaNew England Journal of Medicine, 1983